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Abstract
Surgically correctable forms of primary aldosteronism are characterized by unilateral aldosterone hypersecretion and 
renin suppression, associated with varying degrees of hypertension and hypokalemia. Unilateral aldosterone 
hypersecretion is caused by an aldosterone-producing adenoma (also known as Conn's adenoma and aldosteronoma), 
primary unilateral adrenal hyperplasia and rare cases of aldosterone-producing adrenocortical carcinoma. In these 
forms, unilateral adrenalectomy can cure aldosterone excess and hypokalemia, but not necessarily hypertension. The 
prevalence of primary aldosteronism in the general population is not known. Its prevalence in referred hypertensive 
populations is estimated to be between 6 and 13%, of which 1.5 to 5% have an aldosterone-producing adenoma or 
primary unilateral adrenal hyperplasia. Taking into account referral biases, the prevalence of surgically correctable 
primary aldosteronism is probably less than 1.5% in the hypertensive population and less than 0.3% in the general 
adult population. Surgically correctable primary aldosteronism is sought in patients with hypokalemic, severe or 
resistant forms of hypertension. Recent recommendations suggest screening for primary aldosteronism using the 
aldosterone to renin ratio. Patients with a raised ratio then undergo confirmatory suppression tests. The differential 
diagnosis of hypokalemic hypertension with low renin includes mineralocorticoid excess, with the mineralocorticoid 
being cortisol or 11-deoxycorticosterone, apparent mineralocorticoid excess, pseudo-hypermineralocorticoidism in 
Liddle syndrome or exposure to glycyrrhizic acid. Once the diagnosis is confirmed, adrenal computed tomography is 
performed for all patients. If surgery is considered, taking into consideration the clinical context and the desire of the 
patient, adrenal vein sampling is performed to detect whether or not aldosterone hypersecretion is unilateral. 
Laparoscopic surgery for unilateral aldosterone hypersecretion is associated with a morbidity of about 8%, with most 
complications being minor. It generally results in the normalization of aldosterone secretion and kalemia, and in a large 
decrease in blood pressure, but normotension without treatment is only achieved in half of all cases. Normotension 
following adrenalectomy is more frequent in young patients with recent hypertension than in patients with long-
standing hypertension or a family history of hypertension.
This review deals with the prevalence, presentation, diag-
nosis and management of surgically correctable forms of
primary aldosteronism (PA).
Disease name and synonyms
PA is also called primary hyperaldosteronism. Surgically
correctable forms of the condition are characterized by
unilateral aldosterone hypersecretion. They include
aldosterone-producing adenoma, also termed Conn's
adenoma or aldosteronoma; aldosterone-producing car-
cinoma, a very rare condition; and primary unilateral
adrenal hyperplasia, a condition with a unilateral aldos-
terone hypersecretion documented by adrenal vein sam-
pling (AVS) but without a typical adenoma. In contrast,
idiopathic adrenal hyperplasia and familial hyperaldos-
teronisms type 1 and 2, in which aldosterone hypersecre-
t i o n  i s  b i l a t e r a l ,  a r e  n o t  s u r g i c a l l y  c o r r e c t a b l e .  T h e
subtypes of PA are presented in Table 1. * Correspondence: pierre-francois.plouin@egp.aphp.fr
1 Université Paris Descartes; Assistance Publique-Hôpitaux de Paris, Hôpital 
Européen Georges Pompidou, Hypertension and Clinical Research units, 20 rue 
Leblanc, 75908 Paris cedex 15, France
Full list of author information is available at the end of the articleAmar et al. Orphanet Journal of Rare Diseases 2010, 5:9
http://www.ojrd.com/content/5/1/9
Page 2 of 12
Definition
Hyperaldosteronism is a condition caused by the over-
production of aldosterone, and is characterized by
sodium retention and potassium excretion with resultant
hypertension and hypokalemia. The condition was first
described by J Conn [1], who further distinguished pri-
mary and secondary hyperaldosteronism on the basis of
plasma renin levels, PA being characterized by renin sup-
pression [2]. In a recent clinical practice guideline, PA
was defined as "a group of disorders in which aldosterone
production is inappropriately high, relatively autonomous
from the renin-angiotensin system, and non-suppressible
by sodium loading" [3].
Epidemiology
Prevalence
The prevalence of PA and its various surgically correct-
able subtypes in adults is not known. The prevalence of a
raised aldosterone to renin ratio in the general population
[4] (Figure 1) and in hypertensive patients referred to spe-
cialized centers [5-9] is high (Table 2), but a raised ratio is
not sufficient for diagnosing PA (see [3] and the Diagno-
sis section below). In referral samples involving more
than 1,000 hypertensive patients [5-10], the prevalence of
a raised aldosterone to renin ratio ranged from 6.4 to
22.8%: 5.9 to 11.3% of the patients were confirmed with
PA, and 1.5 to 4.8% had an aldosterone-producing ade-
noma. These figures have probably been overestimated
due to referral biases. Assuming (a) a prevalence of
hypertension of 20% in adult subjects aged 60 [11] or less
in whom adrenalectomy would be considered (see Pre-
diction of blood-pressure outcome below), (b) a conser-
vative two-fold estimate of the over-representation of PA
in hypertensive patients referred to specialized clinics,
and (c) a 3% prevalence of aldosterone-producing ade-
nomas in referred hypertensives, the prevalence of surgi-
cally correctable PA in those aged between 18 and 60
years is less than 1.5% in the hypertensive population and
less than 0.3% in this age group in the general population.
In addition to the low prevalence of surgically correctable
PA, some patients do not undergo surgery and only one
in two operated patients becomes normotensive without
medication following an adrenalectomy (see Manage-
ment and Prognosis below).
Adrenalectomy for Conn's adenoma has been reported
in childhood [12]. The prevalence of surgically correct-
able PA in children and adolescents is not known but is
probably very low.
Incidence
Between 1977 and 1981, the incidence rate of aldoster-
one-producing adenomas for which the patient under-
went surgery was estimated at 0.8 per million individuals
per year in Denmark [13]. This figure is a low estimate, as
it was obtained at a time when the aldosterone to renin
ratio was not in use and computed tomography was not
widely available. A national epidemiological survey in
Japan estimated that 1,450 patients had been diagnosed
with PA of any form in 1997 [14]. In 1997, there were
about 70 million Japanese adults aged 60 or less; thus, the
incidence rate of PA could be estimated to be 2 cases per
100,000 individuals per year in this age group.
Clinical description
Patients with PA present with various degrees of hyper-
tension and/or hypokalemia.
Surgically correctable PA is usually diagnosed in the
fourth or fifth decade. Mean age at PA diagnosis across 9
large series ranged between 45 and 55 years, with an
overall average of 50 years [15-24]. Hypertension was
generally detected 5 to 10 years before PA was diagnosed,
Table 1: Primary aldosteronism subtypes
Surgically correctable subtypes:
Aldosterone-producing adenoma (alias Conn's adenoma, 
aldosteronoma), including:
Renin- or angiotensin-unresponsive adenoma
Renin- or angiotensin-responsive adenoma
Primary unilateral adrenal hyperplasia
Adrenocortical carcinoma with aldosterone hypersecretion
Non surgically correctable subtypes:
Idiopathic adrenal hyperplasia
Familial diseases:
Familial hyperaldosteronism type I (alias glucocorticoid-
remediable aldosteronism), OMIM # 103900
Familial hyperaldosteronism type II, OMIM # 605635
Figure 1 Prevalence of subjects with an elevated ARR. This figure, 
derived from the article of Newton-Cheh et al [4], shows the preva-
lence of an elevated aldosterone to renin ratio (ARR) among subjects 
with or without hypertension (HTN) in relation to various antihyperten-
sive treatments (Tx): Diu, diuretics; ACEI, angiotensin-converting en-
zyme inhibitors; BB, beta-blockers.
% with ARR>26 ng/mU 
No HTN
n=1960
HTN no Tx
n=444
HTN diu
n=281
HTN ACEI
n=279
HTN BB
n=204
Men Women
8 23
3 9
9 13
5 7
26 34Amar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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indicating a significant delay between the onset of PA and
its diagnosis. Grade III hypertension - with blood pres-
sure (BP) levels of 180/110 mmHg or more - or resistant
hypertension - with BP levels of 140/90 mmHg or more
on triple antihypertensive treatment - are reported more
frequently in patients with PA than in those with essential
hypertension [7,25]. The higher frequency of severe
hypertension in patients with PA than in those with
essential hypertension may be the consequence of an
exploration bias, as current recommendations suggest
screening for secondary causes, including PA, in patients
with severe or difficult-to-treat hypertension [26]. Left
ventricular hypertrophy, microalbuminuria, and acute
cardiovascular events are probably more frequent in
patients with PA than in patients with essential hyperten-
sion and similar levels of BP (see T reatment objectives
below).
Hypokalemia, usually defined as serum kalemia ≤ 3.5
mmol/l, is only present in a minority of patients with PA
[5-9]. However, the frequency of hypokalemia is related
to whether P A can be surgically cured. A study with a
large series of patients reported that hypokalemia was
present in 7%, 17% and 48% of patients with essential
hypertension, idiopathic PA, and aldosterone-producing
adenoma, respectively [7]. Hypokalemia may be symp-
tomatic and present as muscular weakness, cramps, par-
esthesia or palpitations with or without atrial fibrillation.
There are rare cases in which PA is revealed by symptom-
atic hypokalemia without hypertension, with or without
adenoma [27].
PA may also be documented in patients presenting with
an incidentally detected adenoma. In a survey of 1096
patients with an adrenal 'incidentaloma', 16 patients were
found to have PA, all of whom were moderately hyperten-
sive [28].
Table 2: Prevalence of a raised aldosterone to renin ratio and of aldosterone-producing adenomas in referral samples or 
samples from a large community
Source and first author ARR threshold, ng/
dL per ng/mL.h-1
Subjects tested, n Raised ARR, % Confirmed PA, % Proven adenoma, %
Community sample of 
hypertensive and non-
hypertensive subjects
Newton-Cheh C, 2007[4] 21*
Men 1574 7 NR NR
Women 1752 13 NR NR
Referral samples of 
>1000 hypertensive 
patients
Nishikawa T, 2000[5] 20 1020 6.4 NR 4.2
Rossi E, 2002[10] 35 1046 12.8 6.3 1.5
Rossi GP, 2006[7] 40 1125 20.4 11.2 4.8
Fogari R, 2007[8] 25 3000 22.8 5.9 1.8
Douma S, 2008[9] 30 1616 20.9 11.3 NR
ARR: aldosterone to renin ratio. PA: primary aldosteronism
Screening tests were considered positive on the basis of a high ARR alone [5,7-9], a composite criterion[7], or the combination of a high ARR and 
a plasma aldosterone concentration of 416 pmol/l (15.0 ng/dL) or more[9]. PA was generally confirmed by a sodium suppression test.
* Direct renin concentration (mU/l) determined by an automated method was converted to plasma renin activity using a conversion factor of 8.2 
(see Funder JW et al, 2008[3])Amar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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Etiology
Etiology of primary aldosteronism
The aldosterone to renin ratio is a heritable trait with a
moderate degree of linkage to chromosome 11p [4]. The
etiology of aldosterone-producing adenoma and primary
unilateral hyperplasia is not known.
Mechanism of hypertension in primary aldosteronism
The main effects of aldosterone are mediated by the min-
eralocorticoid receptor found in the cytosol of epithelial
cells, particularly in the renal collecting duct. Aldoster-
one's major action on epithelial cells is to regulate the
reabsorption of Na+, thereby also influencing the trans-
port of water, K+, and H+ across the membrane. An elec-
trochemical gradient permits the passage of sodium from
the lumen into the epithelial cell through the amiloride-
sensitive epithelial sodium channel. From there, active
transport by the Na+/K+-ATPase carries the Na+ across
the basolateral membrane, from the epithelial cell into
the bloodstream, while simultaneously excreting K+;
water follows the movement of the Na+. Aldosterone
hypersecretion therefore increases exchangeable sodium,
suppresses renin, increases the aldosterone to renin ratio,
causes hypertension, and induces hypokalemia.
Diagnosis of primary aldosteronism
Recent guidelines suggest screening for PA patients with
difficult-to-treat or hypokalemic hypertension using the
aldosterone to renin ratio. Patients with a raised aldoster-
one to renin ratio then undergo a confirmatory test.
Adrenal computed tomography is performed in patients
with confirmed PA to study the morphology of the adre-
nal glands. AVS is then suggested for patients considering
an adrenalectomy, to investigate whether or not aldoster-
one hypersecretion is unilateral (Figure 2) [3].
The aldosterone to renin ratio as a screening test
Aldosterone secretion increases when standing upright
and with decreasing sodium intake. It decreases with
decreasing plasma potassium concentrations and
increasing age. Renin levels are also increased by
decreases in sodium intake and the standing position,
and they also decrease with increasing age. Therefore,
using the aldosterone to renin ratio decreases the intra-
and inter-patient variability in renin and aldosterone lev-
els linked to sodium intake, body position and age[29,30].
The aldosterone to renin ratio was introduced by K Hira-
matsu and colleagues in 1981 as a screening tool to facili-
tate the diagnosis of PA among hypertensive patients
[31].
Although logical and convenient, using the aldosterone
to renin ratio has several limitations. First, renin levels
can be determined as either plasma renin activity or
active renin concentration[32], and aldosterone can be
determined with iodinated or tritiated markers, with or
without an extraction step. Consequently, reference val-
ues and diagnostic thresholds for renin, aldosterone and
the aldosterone to renin ratio are laboratory-specific.
Second, there is no agreement on the aldosterone to renin
ratio cut-off value for diagnosing PA. In a systematic liter-
ature review, the aldosterone to plasma renin activity cut-
off values suggested ranged from 7.2 to 100 ng/dl per ng/
ml.h, corresponding to a 14-fold variation [33]. The most
frequently used cut-off values for aldosterone to plasma
renin activity ratio are in the range of 20 to 50 ng/dl (554
to 1,385 pmol/l) per ng/ml.h; for aldosterone to active
renin concentration, these values are in the range of 2.4 to
4.9 ng/dl (66 to 136 pmol/l) per mU/L (see [3] and Table
2). Third, the aldosterone to renin ratio is positively
related to age, female sex, hypertensive status, and the use
of beta-blockers or hormonal replacement therapy, and is
negatively related to the use of angiotensin-converting
enzyme inhibitors, angiotensin-receptor blockers and
diuretics[4]. The aldosterone to renin ratio may be abnor-
mally high in patients with normal aldosterone levels and
very low renin levels, specifically in some elderly patients,
some patients with a high sodium intake or those taking
beta-blockers, in whom renin is undetectable. Some
experts have therefore suggested that renin values below
an appropriate minimal value (2.5 to 5 mU/l) should not
be used to calculate the aldosterone to renin ratio [7,22].
Some authors suggest screening for PA without the dis-
continuation of medication [34]. However, antihyperten-
sive agents alter the aldosterone to renin ratio. For
Figure 2 Algorithm for screening, diagnosis and management of 
primary aldosteronism. This algorithm, drawn from recent guide-
lines[3], suggests screening patients with difficult-to-treat or hy-
pokalemic hypertension using the aldosterone to renin ratio (ARR). 
Patients with a raised ARR undergo confirmatory tests. Adrenal com-
puted tomography (CT) is performed in patients with confirmed PA. 
Adrenal vein sampling (AVS) is suggested to patients who may have an 
adrenalectomy, to identify whether or not aldosterone hypersecretion 
is unilateral.
Oral salt loading, salt infusion, 
captopril, or fludrocortisone
Hypokalemic or difficult to treat HTN
ARR  yes no
yes CT
yes
no AVS
lateralized
carcinoma
Surgery
considered yes
Surgery
no
Non-
suppressible 
aldosterone 
excessAmar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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example, in the Framingham Offspring Cohort, an aldos-
terone to renin ratio exceeding the value suggestive of PA
was present in 3.1% of normotensive men and 8.8% of
normotensive women, in 7.9% and 23.1% of untreated
hypertensive men and women, and was present in 31.1%
of men or women on beta-blockers (Figure 1)[4]. There-
fore, diuretics and antihypertensive agents should be dis-
continued for at least two weeks and spironolactone,
eplerenone and aliskiren for at least six weeks before
determining the aldosterone to renin ratio. In cases in
which a complete therapeutic washout would not be safe,
antihypertensive medication should be limited to non-
dihydropyridine calcium channel-blockers and alpha-
blockers, which interfere minimally with the measure-
ments[35]. Hypokalemic patients are given potassium
chloride for two reasons: to prevent arrhythmia and
because hypokalemia inhibits aldosterone secretion,
thereby increasing the risk of false negative results[36]. In
addition to antihypertensive agents, drospirenone, a pro-
gestin with antimineralcorticoid activity, may interfere
with laboratory screening and confirmatory testing for
the diagnosis of PAL and should be withdrawn in hyper-
tensive women investigated for aldosteronism[37].
Diagnostic confirmation
Renin-aldosterone dissociation is a key element of all def-
initions of PA. A raised aldosterone to renin ratio is a sen-
sitive but non-specific test ([2-9] and Table 2).
Biochemical confirmatory tests are therefore necessary in
patients with a positive aldosterone to renin ratio, to
avoid costly and invasive imaging tests.
The recent clinical practice guidelines for case detec-
tion, diagnosis, and treatment of patients with PA recom-
mends that patients with a positive aldosterone to renin
ratio undergo any of four suppression tests to confirm or
exclude the diagnosis of PA [3]. This implies that PA is
defined as a non-suppressible aldosterone excess. This
approach might lead to false negatives, as some patients
diagnosed with 'angiotensin-responsive' aldosterone-pro-
ducing adenoma (i.e. with suppressible aldosterone
hypersecretion) can be cured by unilateral adrenalec-
tomy[38,39]. However, this condition is probably rare.
The four suppression tests respectively use oral sodium
loading, oral fludrocortisone, oral captopril, or saline
infusion to suppress aldosterone secretion (Table 3). The
saline infusion test has been carefully analyzed by Rossi et
al. [40]. The sensitivity and specificity of a post-infusion
aldosterone cutoff value of 6.8 ng/dl (188 pmol/l) were 73
and 76%, respectively. However, included patients had
very high aldosterone to renin ratios and these results
may not apply to patients selected with a lower cutoff.
The guideline underlines that, generally, suppression
tests 'have been evaluated only retrospectively, in rela-
tively small series of patients selected with high prior
(pretest) probability of PA, commonly in comparison
with other tests rather than towards a conclusive diagno-
sis of PA' (such as the presence of a lateralized aldoster-
one hypersecretion or the outcome of adrenalectomy).
Thus, further work is needed to improve confirmatory
testing in patients with a high aldosterone to renin ratio.
An alternative approach for confirming PA is to deter-
mine whether the patient has absolute aldosterone hyper-
secretion, which is present if there is a combination of a
high aldosterone to renin ratio and a high level of plasma
or urinary aldosterone [22,41,42]. In one study, 68 out of
347 hypertensives (16.6%) had a raised aldosterone to
renin ratio (>25 ng/dl per ng/ml/h); only 26 (7.5%) also
had a raised serum aldosterone concentration (>8 ng/dl),
of whom only 11 (3.2%) also had a high urine aldosterone
excretion rate (>17 μg/24 h)[41]. One study, taking into
account the variability in repeated aldosterone and aldos-
terone to renin ratio determinations[43], considered PA
to be present if two separate measurements showed a
high aldosterone to renin ratio (>63 pmol/mU) plus high
plasma (>500 pmol/l while lying or >550 pmol/l while
standing) or urinary (>63 nmol/day) aldosterone lev-
els[22] (Figure 3). It is however being debated whether
this approach leads to false negatives. In one report, 4 of
20 patients with unilateral aldosterone hypersecretion at
AVS had normal baseline serum aldosterone concentra-
tions[44]. The precise frequency of this hormonal profile
and the outcome of the adrenalectomy in those con-
cerned are unknown.
Diagnosis of surgically correctable primary 
aldosteronism
As mentioned above, cases with unilateral aldosterone
hypersecretion, including the classic aldosterone-produc-
ing Conn's adenoma, are surgically correctable forms of
PA. Unilateral aldosterone hypersecretion should be con-
firmed by AVS in most or perhaps all cases (see [3] and
Figure 2). Unfortunately, AVS is not widely available, and
is an invasive test exposing patients to potential compli-
cations.
Imaging tests
Computed tomography is the most widely used imaging
test, but magnetic resonance imaging performs simi-
larly[45]. If thin-slice computed tomography shows a sin-
gle hypodense nodule, with the rest of the ipsilateral and
contralateral glands appearing smooth and non-enlarged,
the patient is diagnosed with isolated adrenal adenoma
(Figure 4). The adrenal body and limbs are generally
thicker on the left side than on the right side[46], making
it difficult to diagnose isolated right adrenal adenoma in
some cases. Most aldosterone-producing adenomas are
less than 20 mm in diameter [22,47].Amar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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Non-secreting adenomas are present in about 2% of
adult non-cancer patients and their prevalence increases
with age [48]. The presence of an adenoma in patients
with PA suggests the presence of an aldosterone-produc-
ing adenoma, but it cannot exclude the combination of a
non-secreting adenoma and idiopathic PA[3,44]. The
proportion of patients with a unilateral nodule on their
computed tomography scan or magnetic resonance imag-
ing, but a bilateral or contralateral secretion documented
by AVS, was about 20% in a meta-analysis of 38 stud-
ies[49]. Nonetheless, a non-secreting adenoma is unlikely
in young patients with PA and the presence of an isolated
characteristic adrenal adenoma > 1 cm in PA patients
aged less than 40 [6,50] or less than 55[22] is considered
by some experts as an acceptable surrogate for diagnosing
unilateral aldosterone hypersecretion.
Recent guidelines recommend computed tomography
in all patients with confirmed PA to detect an adrenal car-
cinoma, even if an adrenalectomy is not otherwise con-
sidered[3]. Adrenal carcinomas are very rare, with an
annual incidence estimated at 1-2 per million population,
and present as isolated PA in less than 5% of cases [51].
Adrenal carcinomas presenting as PA are usually larger
than 40 mm in diameter.
Adrenal vein sampling
AVS involves determining aldosterone and cortisol levels
in the inferior vena cava and in the two adrenal veins.
Considering the variability in ACTH secretion and the
acute control of aldosterone secretion by ACTH, some
experts advocate AVS during exogenous ACTH infu-
sion[50]. Other experts suggest AVS in the early morning,
at the time of the spontaneous peak of ACTH secre-
tion[3]. A comparative study reported that exogenous
ACTH infusion does not improve the detection of unilat-
eral aldosterone hypersecretion if the two adrenal veins
are catheterized simultaneously[52].
Table 3: Suppression tests intended to confirm PA
Test Procedure Assays Threshold
Oral sodium loading 
test
Increase sodium intake to >200 
mmol/d for 3 d, provide ClK to keep 
plasma K+
Urinary aldosterone 
determined from the morning 
of d 3 to the morning of d 4
PA unlikely if urinary 
aldosterone <10 μg/24 h
PA likely if urinary aldosterone 
>12 μg/24 h
Saline infusion test Patient in recumbent position for at 
least 1 h, 2 liters of 0.9% saline iv over 
4 h, starting at 0800-0930 h
Kalemia, aldosterone and 
cortisol at the beginning and 
the end of the test
PA unlikely if plasma 
aldosterone <5 ng/dl
PA likely if plasma aldosterone 
>10 ng/dl
Fludrocortisone 
suppression test
0.1 mg oral fludrocortisone every 6 h 
for 4 d. Provide slow-release KCl to 
keep plasma K+ and slow release NaCl 
to maintain urinary sodium excretion 
>3 mmol/kg body weight
Kalemia 4 times a day during 
the 4 days. On day 4
determine plasma cortisol, 
aldosterone and PRA in seated 
posture at 1000 h
PA likely if upright plasma 
aldosterone >6 ng/dl on day 4 
at 1000 h
Captopril challenge 
test
25-50 mg captopril orally after sitting 
for at least 1 hour. Patient in seated 
position for 1 or 2 hours
Plasma aldosterone, PRA and 
cortisol before and 1 or 2 
hours after captopril
PA likely if plasma aldosterone 
is not suppressed by captopril
Adapted from [3]. Abbreviations: PA: primary aldosteronism; PRA: plasma renin activity
Figure 3 Screening, diagnosis and management of primary al-
dosteronism: an alternative algorithm. In this approach[22], PA is 
identified by the presence of absolute aldosterone hypersecretion, i.e. 
the combination of a high aldosterone to renin ratio plus a high level 
of plasma or urinary aldosterone documented from two separate hor-
monal measurements. HTN: hypertension. ARR: aldosterone to renin 
ratio. CT: computed tomography. AVS: adrenal vein sampling.
yes
Hypokalemic or resistant HTN
Surgery
yes
unilat
nodule 
1 cm
CT no AVS
lateralized
2 ARR 
and aldo 
resistant HTN 
or age 55
ARR  yes no no
yesAmar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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Catheter insertion is considered successful if cortisol
concentrations are two to three times higher in the adre-
nal veins than in the inferior vena cava or a peripheral
vein. Aldosterone concentrations in both adrenal veins
are then divided by the corresponding cortisol concentra-
tions. Aldosterone secretion is considered to be lateral-
ized if the aldosterone to cortisol ratio is two to five times
higher on the dominant side than on the non-dominant
side (Table 4).
AVS is a relatively complex procedure, with rates of fail-
ure (documented by a cortisol concentration in the can-
nulated vein(s) below two times higher than those in the
inferior vena cava) between 3 [53] and 22% [54]. It is inva-
sive, and carries a risk of complications of between 0.2
[53] and 5% [55]; complications mainly include adrenal
hematomas, groin hematomas and dissection of adrenal
veins [56]. However, AVS is superior to image-based
techniques for therapeutic decisions, because the objec-
tive of surgery is to suppress unilateral hypersecretion,
not a unilateral nodule. As mentioned above, a unilateral
adenoma is compatible with an incidentaloma associated
with idiopathic PA, particularly in elderly patients. Con-
versely, unilateral hypersecretion may be associated with
primary unilateral adrenal hyperplasia undetectable on
imaging[57]. In a recent series, one in three patients
undergoing adrenalectomy for PA had a lateralized aldos-
terone hypersecretion without a unilateral adenoma[22].
Differential diagnosis
Hypertension with hypokalemia and suppressed renin is
known as mineralocorticoid hypertension, the mineralo-
corticoid involved being aldosterone in the vast majority
o f  c a s e s  [ 5 8 ] .  P A  i s  e a s i l y  e x c l u d e d  b y  t h e  a b s e n c e  o f
aldosterone hypersecretion in cases of mineralocorticoid
hypertension due to an excess secretion of cortisol or
deoxycorticosterone[59], of which some can be corrected
surgically; in apparent mineralocorticoid excess[60]; dur-
ing exposure to glycyrrhizic acid (liquorice)[60]; or in
pseudo-hypermineralocorticoidism due to Liddle syn-
drome [61].
Management including treatment
Treatment objectives
Treatment objectives in patients with PA are to reduce
BP, correct hypokalemia, and to prevent or reverse the
eventual cardiovascular or renal alterations caused by
aldosterone excess. In retrospective case-control studies,
the cardiovascular and renal consequences of hyperten-
sion were reported to be more severe in patients with PA
than in patients with essential hypertension and similar
levels of office BP [63,64]. Thus, correcting for aldoster-
one hypersecretion is a treatment objective per se [65].
Whether PA is associated with an increased prevalence of
glucose metabolism disorders is still disputed [66].
In patients with lateralized aldosterone hypersecretion,
this goal can be achieved by adrenalectomy and probably
by the long-term prescription of aldosterone antago-
nists[67]. Patients' preferences should be taken into
account. Candidates for surgery should be told that the
presence of an aldosterone-producing adenoma poses no
threat of cancer, that surgery may not cure their hyper-
tension completely, and that the frequency of complica-
tions for laparoscopic adrenalectomy is about 8%.
Adrenalectomy
Procedures
With regard to the risk of hypokalemia-induced arrhyth-
mia during anesthesia, hypokalemic patients should be
provided potassium chloride or aldosterone antagonists
before surgery.
A complete unilateral adrenalectomy is required in
patients with primary unilateral adrenal hyperplasia[68].
It is also preferable to adenoma enucleation in cases in
which computed tomography has shown a Conn's ade-
noma, as multiple adenomas are frequent and are not
necessarily identified by preoperative imaging[69].
Besides, the adrenal gland is a small organ, and devascu-
larizing an adenoma frequently results in the devascular-
ization of the entire gland, making conservative surgery
difficult. Laparoscopic surgery, using transperitoneal [70]
or retroperitoneal[71] approaches, is currently the proce-
dure of choice. Mean operating time and length of hospi-
talization are typically 90 min and 4 days [22,70],
respectively . The mean complication rate is 8% [20,70].
Complications of laparoscopic surgery include conver-
sion to open surgery, hematoma due to intraoperative
vascular injury, thromboembolism, pneumothorax or
hemothorax, with most complications being benign.
Figure 4 Computed tomography of the adrenals in three patients 
with primary aldosteronism. Note the moderate hypertrophy of 
both adrenal glands in A, the presence of a left hypodense nodule (ar-
row) in B with a thin right adrenal gland, and the presence of bilateral 
nodules (arrows) in C. All three aspects may coexist with uni- or bilater-
al aldosterone hypersecretion, which must be confirmed using adrenal 
vein sampling. In the patient with the computed tomography shown 
in C, the aldosterone to cortisol ratio was 1.6 in the inferior vena cava, 
0.24 in the left adrenal vein and 42 in the right adrenal vein, indicating 
the presence of a right aldosterone hypersecretion associated with 
non-secreting left adenoma.
AB CAmar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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Morphological/histological findings
The most common aspect is a unilateral, yellow, lipid-
laden adenoma varying in diameter from 5 to 35 mm.
Despite producing aldosterone, the tumor usually con-
sists of zona fasciculata-type cells although zona glomer-
ulosa- or mix ed c e ll-type t umors ha ve been described.
Aldosterone-secreting adrenal carcinomas are extremely
rare. These malignant tumors exceed 40 mm in size with
involvement of local lymph nodes or invasion of adjacent
organs [51].
Outcomes
Surgery abolishes aldosterone hypersecretion and
hypokalemia in most patients with unilateral aldosterone
hypersecretion [17,20-22,72]. It produces a large decrease
in systolic BP (typically -20 to -40 mmHg), and in the
number of antihypertensive medications prescribed (typ-
ically -1 therapeutic class) [19-22].
Patients should be warned that hypertension is not
always cured. Of eleven studies involving 50 or more
patients with PA followed up after unilateral adrenalec-
tomy, seven correctly defined hypertension cure as BP
<140/90 mmHg without treatment, and four used alter-
native definitions or did not report the criteria used to
define normotension (Figure 5). The rate of hypertension
cure was 51% [95%CI 40;62] overall, 44% [95%CI 31;56] in
series using the standard definition of normal BP (<140/
90 mmHg) [16,18-24,72] and 65% [95%CI 49;79] in the
other series[15,17,73,74]. In cases in which an adrenalec-
t om y does  not  cur e  h ype rt ens io n, it  us ua ll y leads t o a
clinically relevant improvement in the control of hyper-
tension, with lower BP levels and/or less antihypertensive
medication required. Seven of the 11 studies reported
that BP improved without cure in 18 to 71% of patients,
leading to hypertension benefit (cure or improvement) in
74 to 100% of operated patients.
Prediction of blood-pressure outcome
A dominant aldosterone-dependant component of hyper-
tension and a low probability of associated essential
hypertension are predictive of a better BP outcome after
adrenalectomy.
In univariate analysis, several patient characteristics
that suggest aldosterone-dependent hypertension have
Table 4: Proposed thresholds for interpreting results from adrenal vein sampling
Adrenal to IVC cortisol ratio Dominant to non-dominant 
A/C ratio
Non-dominant to IVC A/C 
ratio
Adrenal venous sampling without ACTH stimulation
Rossi, 2008[21] >1.1 >2 Not used
Stowasser, 2004[44] >3 >2* <1
Zarnegar, 2008[23] >1 >4 or 5 Not used
Letavernier,2008[22] >2 >5 Not used
Mulatero, 2008[80] >2 >4 <1
Adrenal venous sampling with ACTH stimulation
Espiner, 2003[81] >2 >4 <1
Murashima, 2008[82] >10 >4 Not used
Young, 2004[50] >5 >4 Not used
Auchus, 2009[83] >3 >4 Not used
Interpreting adrenal vein sampling results involves accounting for the ratio of cortisol concentrations between the adrenal gland veins and 
the inferior vena cava (IVC) or a peripheral vein, to confirm that adrenal gland veins have been effectively cannulated. The lateralizing ratio, 
i.e. the ratio between the aldosterone to cortisol (A/C) ratios determined in the dominant (D) and non-dominant (ND) sides, is also considered 
(see text).
*Dominant to IVC A/C ratioAmar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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been associated with a favorable outcome: they include
the presence of a typical and large aldosterone-producing
adenoma on imaging studies or at pathological examina-
tion [15,17,20,24,72]; high urinary aldosterone excretion,
low plasma renin or low serum potassium lev-
els[18,22,72]; the absence of an increase in the plasma
aldosterone concentration after standing up[74] and the
preoperative normalization of BP on monotherapy with
high-dose spironolactone[17,75]. Conversely, non-spe-
cific characteristics usually present in essential and/or
severe hypertension have been associated with a poor BP
outcome of adrenalectomy: they include older age [15,17-
20,72,74-76] or longer duration of hypertension before
surgery[17-19,21,22,72]; higher body-mass index
[21,22,72] male sex [15,20,72,74]; a history of essential
hypertension in first-degree relatives[17,18]; preoperative
BP[17,21] and number of prescribed antihypertensive
drugs [17-20,72]; and the presence of remodeling of resis-
tance arteries[21].
Various factors have each been associated with a less
favorable BP outcome in at least one multivariate model:
lower urinary aldosterone excretion; a small adenoma or
the presence of contralateral morphological abnormali-
ties; the absence of BP control in patients on spironolac-
tone; a higher number of antihypertensive medications
required to control BP; older age or a longer history of
hypertension; higher body mass index; male sex; and the
presence of a family history of hyperten-
sion[15,17,18,20,22,72]. The validity of these multivariate
analyses is threatened by small sample sizes; comparisons
across studies are difficult because the various models did
not include the same variables.
The relevance of these prognostic markers for selecting
patients for surgery should not be overemphasized, as
they do not take into account the invariable cure of
hypokalemia and hyperaldosteronism by adrenalectomy
and provide only a weak prediction of the BP benefit in
individual patients. For example, according to the only
prediction model validated to date, number of antihyper-
tensive medication ≤ 2, a body mass index ≤ 25 kg/m2, a
duration of hypertension ≤ 6 years and female sex are the
best predictors of hypertension cure following adrenalec-
tomy[24]. However, even if none of these features was
present in an individual patient, this patient still had a
25% probability of being completely cured by an adrena-
lectomy and if not cured, hypertension was almost always
better controlled. In another study in which the mean
systolic BP decrease was -25 mmHg after surgery, the
clinical impact of statistically significant prognostic fac-
tors was limited: the mean systolic BP decrease was only
3 mmHg less (-22 instead of -25 mmHg) in patients with a
0.5 mmol/l higher level of serum potassium before sur-
gery, the most powerful predictor of unfavorable out-
comes[22].
Long-term benefits
Operated patients can expect to be completely or par-
tially weaned from mineralocorticoid antagonists or non-
specific antihypertensive medication. The alternative to
surgery is lifelong medication intended to correct or pre-
vent the deleterious direct or indirect effects of hyperal-
dosteronism. Younger patients have a longer life
expectancy and therefore derive a greater benefit from
surgery. They also carry the smallest anesthetic risk. Early
diagnosis of lateralized PA is therefore of paramount
importance. The benefit-risk ratio is more balanced in
older patients, especially if their antihypertensive medi-
cation has compelling indications, such as beta-blockers
for coronary artery disease or angiotensin-converting
enzyme and spironolactone for heart failure.
Alternatives to adrenalectomy
Mineralocorticoid receptor antagonists - spironolactone
and eplerenone - provide a specific treatment for PA in
patients who are not candidates for surgery. Unfortu-
nately, only a few of these patients show a good BP
response to spironolactone monotherapy [77]. Further-
more, long-term tolerance of spironolactone at doses
exceeding 50 mg per day is poor[78]. There is no pub-
lished evidence to suggest that high doses of eplerenone
are more effective and better tolerated than spironolac-
t o n e  i n  p a t i e n t s  w i t h  P A.  I f  n e c e s s a r y ,  l o w e r  d o s e s  o f
aldosterone receptor antagonists may be associated with
non-specific antihypertensive agents.
Figure 5 Blood pressure outcome of adrenalectomy in primary 
aldosteronism. Percentages of patients with hypertension cure fol-
lowing surgery in studies with more than 50 patients. Studies are clas-
sified according to the definition used for hypertension cure. One 
study was discarded[79] because of a large overlap with a more recent 
study[22]. One study involved patients from two centers as a deriva-
tion sample and a validation sample respectively [24]. Due to signifi-
cant heterogeneity across studies, a random effects model was used to 
estimate the combined effects.
Overall (I-squared = 92.4%)
Letavernier (2008)
Zarnegar (2008b)
Gleason (1993)
Sawka (2001)
Obara (1992)
Zarnegar (2008a)
BP < 140/90 mmHg
Pang (2007)
Proye (1998)
Lumachi (2005)
Subtotal  (I-squared = 91.3%)
Subtotal  (I-squared = 86.9%)
Rossi (2008)
Shen (1999)
BP < 160/95 mmHg / No definition
Stowasser (1994)
51 [40;62]
32 [25;39]
43 [32;55]
70 [60;80]
33 [24;43]
62 [50;73]
35 [26;45]
34 [22;47]
56 [46;66]
72 [63;81]
44 [31;56]
65 [49;79]
30 [18;43]
85 [76;92]
55 [42;67]
% [95% CI]Amar et al. Orphanet Journal of Rare Diseases 2010, 5:9
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Unresolved questions
The etiopathogenesis and genomics of PA and aldoster-
one-producing adenomas are currently being studied by
several research groups. Collaborative prospective stud-
ies are needed to document and standardize critical steps
in the diagnosis of PA and the confirmation of lateralized
PA in relation to surgically correctable PA. This specifi-
cally applies to studying the advantages that post-sup-
pression plasma aldosterone concentrations have over
basal concentrations, and the cut-off values that are used
to detect a clinically relevant lateralizing ratio at AVS. As
the rate of cure of hypertension following adrenalectomy
is only 50%, there is also a need for randomized trials
comparing the safety, acceptability and efficacy of surgery
and aldosterone antagonists, regarding BP and target
organ damage.
Conclusions
Surgically correctable PA is sought in patients with
hypokalemic or difficult-to-treat hypertension, and is
diagnosed by the presence of unilateral aldosterone
hypersecretion at AVS. Surgery is particularly useful for
young PA patients, who can be completely cured, and for
PA patients with resistant hypertension, whose BP con-
trol can be markedly improved.
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